Valo Therapeutics is pioneering innovative immunotherapy solutions aimed at revolutionizing cancer treatment and prevention. Central to their approach is the PeptiCRAd technology, which combines oncolytic adenoviruses with tumor-specific peptides. This platform leverages the immunogenic properties of adenoviruses to enhance the immune response against cancer cells. By using these viruses as carriers for tumor-specific peptides, ValoTx aims to redirect the immune system's focus from attacking the virus to targeting and destroying cancer cells. This method allows for a highly adaptable treatment that can be customized for various cancer types by simply altering the peptides coated onto the viral vector.

In addition to PeptiCRAd, Valo Therapeutics is also developing the PeptiENV platform, which utilizes oncolytic enveloped viruses to carry tumor-specific peptides. This technology boasts a significantly higher capacity for peptide delivery compared to PeptiCRAd, potentially enhancing immune responses. ValoTx's suite of technologies, including PeptiVAX and PeptiBAC, further supports the development of personalized cancer vaccines by integrating disease-specific peptide targets. Overall, Valo Therapeutics is focused on creating a robust and versatile immunotherapy landscape that can effectively engage the immune system in the fight against cancer.

Finland

Valo Therapeutics (ValoTx) is a developer of novel immunotherapies in cancer and infectious disease. Our unique approach to immunotherapy, based on oncolytic viruses and viral vectors combined with disease-specific peptides, delivers highly adaptable and immunogenic therapeutic vaccination platforms. A spin-out company from the University of Helsinki, Finland, Valo Tx has assembled a talented team of immunotherapy experts, who together with the founding scientists have the necessary expertise to take its patented technology through clinical development and make it available to patients. 

Valo Therapeutics

Company Details